SyntheticMR publishes Annual Report for 2025
Idag, 08:01
SyntheticMR publishes Annual Report for 2025
SyntheticMR AB (publ) hereby announces that the Group´s Annual Report for 2025 has been published.
The Annual Report is also available on SyntheticMRs website www.syntheticmr.com
The English Annual Report is a translation of the Swedish version. The Swedish Annual Report shall prevail in case of conflict.
SyntheticMR AB (publ) develops and markets medical device imaging solutions* designed to enhance efficiency and diagnostic precision in neuroimaging. The company offers a comprehensive product portfolio, including the SyMRI® solution, which measures absolute brain tissue properties and, from a single fast scan, generates multiple contrast-weighted images, performs automated biomarker segmentation, and provides quantitative data, as well as the AI-powered cNeuro® product suite, which supports clinicians in the assessment and management of neurological disorders.
The company is listed on the Spotlight Stock Market in Stockholm and is headquartered in Linköping, Sweden, with an additional office in Tampere, Finland. For more information, visit syntheticmr.com and combinostics.com.
*Regulatory clearances may vary by product and version, and indications for use may differ between countries/regions.
For more information, please contact:
Lena Åredal, CEO
Phone: +4676 770 99 08
E-Mail: lena.aredal@syntheticmr.com
Johanna Norén, CFO & Head of Investor Relations
Phone:+4670 619 21 00
E-Mail: johanna.noren@syntheticmr.com
Ämnen i artikeln
SyntheticMR publishes Annual Report for 2025
Idag, 08:01
SyntheticMR publishes Annual Report for 2025
SyntheticMR AB (publ) hereby announces that the Group´s Annual Report for 2025 has been published.
The Annual Report is also available on SyntheticMRs website www.syntheticmr.com
The English Annual Report is a translation of the Swedish version. The Swedish Annual Report shall prevail in case of conflict.
SyntheticMR AB (publ) develops and markets medical device imaging solutions* designed to enhance efficiency and diagnostic precision in neuroimaging. The company offers a comprehensive product portfolio, including the SyMRI® solution, which measures absolute brain tissue properties and, from a single fast scan, generates multiple contrast-weighted images, performs automated biomarker segmentation, and provides quantitative data, as well as the AI-powered cNeuro® product suite, which supports clinicians in the assessment and management of neurological disorders.
The company is listed on the Spotlight Stock Market in Stockholm and is headquartered in Linköping, Sweden, with an additional office in Tampere, Finland. For more information, visit syntheticmr.com and combinostics.com.
*Regulatory clearances may vary by product and version, and indications for use may differ between countries/regions.
For more information, please contact:
Lena Åredal, CEO
Phone: +4676 770 99 08
E-Mail: lena.aredal@syntheticmr.com
Johanna Norén, CFO & Head of Investor Relations
Phone:+4670 619 21 00
E-Mail: johanna.noren@syntheticmr.com
Ämnen i artikeln
Analys
Analys
Marknadsöversikt
1 DAG %
Senast
1 mån
